Literature DB >> 21567205

TNFRSF1A [corrected] R92Q mutation, autoinflammatory symptoms and multiple sclerosis in a cohort from Argentina.

Marcelo A Kauffman1, Dolores Gonzalez-Morón, Orlando Garcea, Andrés María Villa.   

Abstract

Systemic autoinflammatory diseases are genetic disorders characterized by seemingly unprovoked inflammation, without major involvement of the adaptive immune system. Among them it is recognized the TNF receptor associated periodic syndrome (TRAPS) caused by mutations in the TNFRSF1A gene and characterized by symptoms such as recurrent high fevers, rash, abdominal pain, arthralgia and myalgia. Recent studies have recognized the potential role of TNFRSF1A mutations in Multiple Sclerosis (MS). Our aim was to investigate the role of TNFRSF1A R92Q gene mutation in a cohort of 90 Argentinean MS patients, where we determined the frequency of the TNFRSF1A R92Q mutation. We also compared autoinflammatory symptoms, MS clinical characteristics and treatment response and tolerability in R92Q carriers and non-carriers. Also, we used a case-control study design to obtain the genotypes of 78 healthy controls and assess the role of this mutation as a risk factor for MS. We found that five patients (5.5%) carried the R92Q mutation, four reported autoinflammatory symptoms previous to MS onset. We found no differences in MS clinical features, treatment response and tolerability between carriers and non-carriers. R92Q mutation was more frequent in MS patients as compared to controls. This increases the risk to develop MS in about 4.5 times. The TNFRSF1A R92Q mutation is a common finding in Argentinean MS patients. This genetic variant might be a risk factor for MS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21567205     DOI: 10.1007/s11033-011-0716-3

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  22 in total

1.  [Bell's palsy as a form of presentation of multiple sclerosis].

Authors:  M T Adeva-Bartolomé; M T Blázquez-Estrada; J Fermoso-García
Journal:  Rev Neurol       Date:  1999 Mar 1-15       Impact factor: 0.870

2.  Sacroileitis and pericarditis: atypical presentation of tumor necrosis factor receptor-associated periodic syndrome and response to etanercept therapy.

Authors:  L Cantarini; O M Lucherini; R Cimaz; C T Baldari; F Laghi Pasini; M Galeazzi
Journal:  Clin Exp Rheumatol       Date:  2010-05-14       Impact factor: 4.473

3.  Neutrophils from patients with TNFRSF1A mutations display resistance to tumor necrosis factor-induced apoptosis: pathogenetic and clinical implications.

Authors:  Andrea D'Osualdo; Francesca Ferlito; Ignazia Prigione; Laura Obici; Antonella Meini; Francesco Zulian; Alessandra Pontillo; Fabrizia Corona; Roberto Barcellona; Marco Di Duca; Giuseppe Santamaria; Francesco Traverso; Paolo Picco; Maurizia Baldi; Alessandro Plebani; Roberto Ravazzolo; Isabella Ceccherini; Alberto Martini; Marco Gattorno
Journal:  Arthritis Rheum       Date:  2006-03

4.  Long-term clinical profile of children with the low-penetrance R92Q mutation of the TNFRSF1A gene.

Authors:  M A Pelagatti; A Meini; R Caorsi; M Cattalini; S Federici; F Zulian; G Calcagno; A Tommasini; G Bossi; M P Sormani; F Caroli; A Plebani; I Ceccherini; A Martini; M Gattorno
Journal:  Arthritis Rheum       Date:  2011-04

5.  Familial Hibernian fever.

Authors:  L M Williamson; D Hull; R Mehta; W G Reeves; B H Robinson; P J Toghill
Journal:  Q J Med       Date:  1982

Review 6.  The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder.

Authors:  Keith M Hull; Elizabeth Drewe; Ivona Aksentijevich; Harjot K Singh; Kondi Wong; Elizabeth M McDermott; Jane Dean; Richard J Powell; Daniel L Kastner
Journal:  Medicine (Baltimore)       Date:  2002-09       Impact factor: 1.889

7.  Infevers: an evolving mutation database for auto-inflammatory syndromes.

Authors:  Isabelle Touitou; Suzanne Lesage; Michael McDermott; Laurence Cuisset; Hal Hoffman; Catherine Dode; Nitza Shoham; Ebun Aganna; Jean-Pierre Hugot; Carol Wise; Hans Waterham; Denis Pugnere; Jacques Demaille; Cyril Sarrauste de Menthiere
Journal:  Hum Mutat       Date:  2004-09       Impact factor: 4.878

8.  Idiopathic recurrent pericarditis refractory to colchicine treatment can reveal tumor necrosis factor receptor-associated periodic syndrome.

Authors:  L Cantarini; O M Lucherini; R Cimaz; C T Baldari; F Bellisai; S Rossi Paccani; F Laghi Pasini; P L Capecchi; G D Sebastiani; M Galeazzi
Journal:  Int J Immunopathol Pharmacol       Date:  2009 Oct-Dec       Impact factor: 3.219

9.  Multiple sclerosis and the TNFRSF1A R92Q mutation: clinical characteristics of 21 cases.

Authors:  T Kümpfel; L-A Hoffmann; H Pellkofer; W Pöllmann; W Feneberg; R Hohlfeld; P Lohse
Journal:  Neurology       Date:  2008-11-25       Impact factor: 9.910

10.  Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

Authors:  W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

View more
  4 in total

1.  Clinical relevance and functional consequences of the TNFRSF1A multiple sclerosis locus.

Authors:  Linda Ottoboni; Irene Y Frohlich; Michelle Lee; Brian C Healy; Brendan T Keenan; Zongqi Xia; Tanuja Chitnis; Charles R Guttmann; Samia J Khoury; Howard L Weiner; David A Hafler; Philip L De Jager
Journal:  Neurology       Date:  2013-10-30       Impact factor: 9.910

2.  Role of tumour necrosis factor (TNF)-α and TNFRSF1A R92Q mutation in the pathogenesis of TNF receptor-associated periodic syndrome and multiple sclerosis.

Authors:  A Caminero; M Comabella; X Montalban
Journal:  Clin Exp Immunol       Date:  2011-12       Impact factor: 4.330

Review 3.  Central nervous system manifestations of monogenic autoinflammatory disorders and the neurotropic features of SARS-CoV-2: Drawing the parallels.

Authors:  Thomas Renson; Lorraine Hamiwka; Susanne Benseler
Journal:  Front Pediatr       Date:  2022-08-10       Impact factor: 3.569

4.  DNA methylation as clinically useful biomarkers-light at the end of the tunnel.

Authors:  Victor V Levenson; Anatoliy A Melnikov
Journal:  Pharmaceuticals (Basel)       Date:  2012-01-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.